Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - eformoterol fumarate dihydrate; budesonide -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

usana australia pty ltd - cholecalciferol,concentrated omega-3 triglycerides - fish -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

lacorium health international pty ltd - tolnaftate, quantity: 10 mg/g - cream - excipient ingredients: menthol; purified water; glycerol; monobasic sodium phosphate; cetyl alcohol; aloe vera; lavender oil; propylene glycol; urea; dl-alpha-tocopheryl acetate; polysorbate 60; cetostearyl alcohol; benzalkonium chloride; ceteareth-20; white soft paraffin; light liquid paraffin - for the treatment of athlete's foot and ringworm. antifungal action relieves itchy, burning and irritated feet. provides soothing, cooling effect for irritated, painful feet. provides rapid, effective relief of itchy, cracked skin associated with athlete's foot. protects feet from various micro-organisms, bacteria and germs. moisturizes and hydrates dry,cracked, flaky skin.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - methyldopa -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

maclab australia pty ltd - green lipped mussel dried -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

blueskygreenearth herbs pty ltd - leuzea uniflorum,magnolia officinalis -

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 80ug equivalent to 100 µg metered dose;  ;  ;  ; formoterol fumarate 4.5ug equivalent to 6 µg metered dose;   - powder for inhalation - active: budesonide 80ug equivalent to 100 µg metered dose       formoterol fumarate 4.5ug equivalent to 6 µg metered dose   excipient: lactose monohydrate - symbicort turbuhaler is indicated in the treatment of asthma to achieve overall asthma control, including the prevention and relief of symptoms as well as the reduction of the risk of exacerbations. symbicort turbuhaler is suitable for any asthma severity, where the use of inhaled corticosteroids is appropriate.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 160ug equivalent to 200 µg metered dose;  ;  ;  ; formoterol fumarate 4.5ug equivalent to 6 µg metered dose;   - powder for inhalation - active: budesonide 160ug equivalent to 200 µg metered dose       formoterol fumarate 4.5ug equivalent to 6 µg metered dose   excipient: lactose monohydrate - symbicort turbuhaler is indicated in the treatment of asthma to achieve overall asthma control, including the prevention and relief of symptoms as well as the reduction of the risk of exacerbations. symbicort turbuhaler is suitable for any asthma severity, where the use of inhaled corticosteroids is appropriate.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 320ug equivalent to 400 µg metered dose;  ;  ;  ; formoterol fumarate 9ug equivalent to 12 µg metered dose;   - powder for inhalation - active: budesonide 320ug equivalent to 400 µg metered dose       formoterol fumarate 9ug equivalent to 12 µg metered dose   excipient: lactose monohydrate - symbicort turbuhaler is indicated in the treatment of asthma to achieve overall asthma control, including the prevention and relief of symptoms as well as the reduction of the risk of exacerbations. symbicort turbuhaler is suitable for any asthma severity, where the use of inhaled corticosteroids is appropriate.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 80ug;  ;  ;  ; formoterol fumarate 4.5ug;   - aerosol inhaler, metered dose - 100/6 - active: budesonide 80ug       formoterol fumarate 4.5ug   excipient: apaflurane macrogol 1000 povidone - symbicort rapihaler 100/6 is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate. this includes: · patients who are not adequately controlled with inhaled corticosteroid therapy and ?as needed? inhaled short-acting beta-2 adrenoceptor agonists. · patients who are already adequately controlled on regular separate long acting beta-agonist and inhaled corticosteroid therapies.